Recent Updates
Recently added Catalysts
HCTI Positive Sentiment Score: 85/100

Healthcare Triangle, Inc. Signs Definitive Agreement with Teyame AI LLC which is forecasted to generate $38M in incremental NTM Revenue and incremental NTM EBITDA of $5M in addition to expanding its SaaS Footprint in Eur

Key Takeaway: Healthcare Triangle, Inc. (HCTI) has signed a definitive agreement to acquire Teyame AI LLC, which is anticipated to generate $38 million in additional next twelve months (NTM) revenue and $5 million in NTM EBITDA. The acquisition, part of a strategic move to enhance HCTI's healthcare and life sciences digital solutions, will also expand its SaaS offerings in Europe and Latin America. The deal, valued at up to $50 million, includes cash, stock, and earnouts, with a closing date expected on January 29, 2026. The integration of Teyame’s AI-powered customer experience platforms is projected to foster an intelligent ecosystem for patient engagement.

Market Sentiment Analysis

POSITIVE FACTORS

  • Projected generation of $38M in incremental NTM Revenue.
  • Acquisition expected to enhance HCTI’s financial performance and shareholder value.
  • Expansion into Europe and Latin America strengthens HCTI's SaaS footprint.
  • Combining expertise in AI-powered engagement with healthcare technology.

Full Press Release Details

Triangle, Inc. Signs Definitive Agreement with Teyame AI LLC which is forecasted to generate $38M in incremental NTM Revenue and incremental
NTM EBITDA of $5M in addition to expanding its SaaS Footprint in Europe and Latin America
Calif., January 22, 2026 (PR NEWSWIRE) - Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"),
a leader in digital transformation solutions for healthcare and life sciences, today announces that it has entered into an Definitive
Agreement with Teyame AI LLC, a St Kitts and Nevis corporation ("Teyame"), as part of its planned acquisition of the shares
of Teyame 360 SL and Datono Mediacion SL, companies incorporated in Spain ("Assets"), which are run together as a Spain-based
leader in AI-powered omnichannel customer experience (CX) solutions. This acquisition would position the Company as a global force in
AI-powered customer and patient engagement.
proposed transaction contemplates up to approximately $50 million of total consideration, consisting of a combination of cash, shares
of the Company's common stock, shares of non-voting convertible preferred stock, and contingent earnout-based equity consideration,
and anticipate closing the transaction on January 29, 2026 subject to the required shareholder approval, and other customary closing
conditions. Notwithstanding the closing timeline, the parties agreed that the transaction contemplated by this Agreement shall be deemed
effective as of January 1st, 2026. This communication does not constitute a solicitation of any proxy, vote or approval.
on financial information the Company has received from Teyame, the Assets generated approximately $32 million in incremental annual revenue
and approximately $3.6 million in incremental EBITDA for fiscal year 2025. The planned acquisition represents a pivotal moment in HCTI's
evolution from healthcare IT provider to comprehensive digital innovator and is expected to significantly enhance HCTI's financial
performance and shareholder value.
transaction will bring real world lived experience of Agentic Gen AI and is about to change the game for HCTI. It's where the rubber
meets the road in AI" added David Ayanoglou, Chief Financial Officer of HCTI.
are pleased to take this decisive step with the signing of the Definitive agreement. Integrating these AI-powered engagement platforms
with HCTI's healthcare technologies positions us to deliver a next-generation, intelligent ecosystem for patients, providers, and
expanding SaaS Footprint into Europe and Latin America."- Sujatha Ramesh, Chief Operating Officer, Principal Executive
Officer, and Director, Board of Directors, HCTI.
planned acquisition is slated to be a critical step in HCTI's broader strategy focused on:
strategic acquisition will combine HCTI's deep healthcare technology expertise with the acquired Assets' AI automation customer
engagement platform(s), so that an integrated ecosystem can be created where every patient touchpoint would become intelligent, personalized,
and outcome focused.
Triangle, Inc. based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry
knowledge and expertise. We support healthcare organizations including hospitals and health systems, payers, and pharma/life sciences
organizations in their effort to improve health outcomes through better utilization of the data and information technologies that they
rely on. Healthcare Triangle achieves HITRUST Certification for Cloud and Data Platform (CaDP), marketed as CloudEz and DataEz .
HITRUST Risk-based, 2-year (r2) Certified status demonstrates to our clients the highest standards for data protection and information
security. Healthcare Triangle enables the adoption of new technologies, data enlightenment, business agility, and response to immediate
business needs and competitive threats. The highly regulated healthcare and life sciences industries rely on Healthcare Triangle for
expertise in digital transformation encompassing the cloud, security and compliance, data lifecycle management, healthcare interoperability,
and clinical & business performance optimization.
Teyame 360 SL and Datono Mediacion SL
AI Innovation and Customer Engagement Meets Healthcare Expertise
Assets which are headquartered in Madrid, have built a sophisticated platform that seamlessly blends artificial intelligence with human
expertise, currently serving banking and insurance clients while piloting breakthrough healthcare applications. The company's technology
stack includes advanced chatbot automation, multilingual patient engagement tools, and real-time analytics, capabilities that become
exponentially more powerful when integrated with HCTI's clinical systems.
highlights of the Assets' innovations include:
Statements and Safe Harbor Notice
statements other than statements of historical facts included in this press release are "forward-looking statements" (as defined
in the Private Securities Litigation Reform Act of 1995), and include, among others, statements regarding the consummation of the private
placement, satisfaction of the customary closing conditions of the private placement and the use of the proceeds therefrom. Such forward-looking
statements include our expectations and those statements that use forward-looking words such as "projected," "expect,"
"possibility" and "anticipate." The achievement or success of the matters covered by such forward-looking statements
involve significant risks, uncertainties, and assumptions, including market and other conditions. Actual results could differ materially
from current projections or implied results. Investors should read the risk factors out lined in the company's annual report on form
10-K for the year ended December 31, 2024, on file with the Securities Exchange Commission (the "SEC") and in previous filings,
subsequent filings and future periodic reports filed with the SEC. All the company's forward-looking statements are expressly qualified
by all such risk factors and other cautionary statements.

Frequently Asked Questions

What is the significance of HCTI's agreement with Teyame AI?

The agreement is expected to enhance HCTI's revenue by $38M and EBITDA by $5M.

When is the closing date for the Teyame acquisition?

The acquisition is anticipated to close on January 29, 2026, pending approvals.

How much will the total consideration for the acquisition be?

The total consideration for the transaction is approximately $50 million.

What will the acquisition bring to HCTI?

It will provide AI-powered engagement platforms, enhancing patient interactions.

Where are Teyame's Assets based?

The Assets, Teyame 360 SL and Datono Mediacion SL, are based in Spain.

Last updated: Jan 22, 2026